People · Operator

Steven F. Bauwens, PhD

Named in public records as an officer, director or promoter · active 2015–2015 · Other Technology

1
Companies
5
Filings
$15.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Edlogics, LLCOther TechnologySeries A$15.0M$406.0M2015
Operator network

Steven F. Bauwens, PhD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Tommy G. Thompson · 7 companies · 1 sharedTommy G. ThompsonDavid L. Bernd · 3 companies · 1 sharedDavid L. BerndDavid Ann Kaufman · 1 companies · 1 sharedDavid Ann KaufmanJerry T. Gulley II · 1 companies · 1 sharedJerry T. Gulley IIKenneth Ann Melani · 1 companies · 1 sharedKenneth Ann MelaniKirk T. Woodruff, MAOD · 1 companies · 1 sharedKirk T. Woodruff,…Mary Ann Cope, R.Ph. · 1 companies · 1 sharedMary Ann Cope, R.…Michael J Groh, PharmD · 1 companies · 1 sharedMichael J Groh, P…Scott W. Reed · 1 companies · 1 sharedScott W. ReedSteven F. Bauwens · 1 companies · 1 sharedSteven F. BauwensThomas Chamberlain, Pharm.D. · 1 companies · 1 sharedThomas Chamberlai…Thomas Chamberlain, PharmD · 1 companies · 1 sharedThomas Chamberlai…Edlogics, LLC · $15.0M raisedEdlogics, LLCSteven F. Bauwens, PhDSP
Steven F. Bauwens, PhD Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Steven F. Bauwens, PhD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Tommy G. Thompson17
David L. Bernd13
Steven F. Bauwens11
Thomas Chamberlain, Pharm.D.11
Mary Ann Cope, R.Ph.11
Michael J Groh, PharmD11
Scott W. Reed11
Thomas Chamberlain, PharmD11
Kenneth Ann Melani11
David Ann Kaufman11
Kirk T. Woodruff, MAOD11
Jerry T. Gulley II11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.